Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1215275-54-9

Post Buying Request

1215275-54-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1215275-54-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1215275-54-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,5,2,7 and 5 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1215275-54:
(9*1)+(8*2)+(7*1)+(6*5)+(5*2)+(4*7)+(3*5)+(2*5)+(1*4)=129
129 % 10 = 9
So 1215275-54-9 is a valid CAS Registry Number.

1215275-54-9Downstream Products

1215275-54-9Relevant articles and documents

Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the Na+/H+ Exchanger Type 3 (NHE3)

Rackelmann, Nils,Matter, Hans,Englert, Heinrich,Follmann, Markus,Maier, Thomas,Weston, John,Arndt, Petra,Heyse, Winfried,Mertsch, Katharina,Wirth, Klaus,Bialy, Laurent

, p. 8812 - 8829 (2016)

The design, synthesis, and structure-activity relationship of 1-phenoxy-2-aminoindanes as inhibitors of the Na+/H+ exchanger type 3 (NHE3) are described based on a hit from high-throughput screening (HTS). The chemical optimization resulted in the discovery of potent, selective, and orally bioavailable NHE3 inhibitors with 13d as best compound, showing high in vitro permeability and lacking CYP2D6 inhibition as main optimization parameters. Aligning 1-phenoxy-2-aminoindanes onto the X-ray structure of 13d then provided 3D-QSAR models for NHE3 inhibition capturing guidelines for optimization. These models showed good correlation coefficients and allowed for activity estimation. In silico ADMET models for Caco-2 permeability and CYP2D6 inhibition were also successfully applied for this series. Moreover, docking into the CYP2D6 X-ray structure provided a reliable alignment for 3D-QSAR models. Finally 13d, renamed as SAR197, was characterized in vitro and by in vivo pharmacokinetic (PK) and pharmacological studies to unveil its potential for reduction of obstructive sleep apneas.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1215275-54-9